Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

NCT01692366 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: SAR302503

Sponsor

Bristol-Myers Squibb